Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Ruth Plummer

Newcastle AuthorsTitleYearFull text
Dr Tom Andrew
Professor Ruth Plummer
Professor Nick Reynolds
Guin Brownell
Professor Penny Lovat
et al.		A hybrid machine learning approach for the personalized prognostication of aggressive skin cancers2025
Dr Tom Andrew
Professor Ruth Plummer
Professor Penny Lovat
Aidan Rose
A multivariable disease-specific model enhances prognostication beyond current Merkel cell carcinoma staging: An international cohort study of 10,958 patients2025
Dr Tom Andrew
Grant Richardson
Professor Philip Sloan
Professor Ruth Plummer
Professor Penny Lovat
Multimodal AI and tumour microenvironment integration predicts metastasis in cutaneous melanoma2025
Professor Ruth Plummer
Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action2025
Professor Ruth Plummer
Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects2025
Professor Ruth Plummer
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma2024
Professor Alastair Greystoke
Professor Ruth Plummer
Dr Christoph Oing
Dr Pasquale Rescigno
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis2024
Dr Victoria Coyle
Professor Ruth Plummer
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT2024
Dr Abi Gault
Dr Linda Hogarth
Dr Kristian Williams
Professor Alastair Greystoke
Professor Neil Rajan
et al.		Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study2024
Professor Ruth Plummer
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial2024
Dr Yvette Drew
Professor Ruth Plummer
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study2024
Sarah Rae
Ellie Taylor
Joseph Hoben
Dr Christoph Oing
Professor Alastair Greystoke
et al.		Social determinants of health inequalities in early phase clinical trials in Northern England2024
Julieann Sludden
Professor Gareth Veal
Professor Ruth Plummer
A Phase 1/2A trial of idroxioleic acid: First-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma2023
Professor Gareth Veal
Professor Steve Wedge
Dr Christopher Bacon
Professor Philip Sloan
Professor Alastair Greystoke
et al.		A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer2023
Dr Fadhel Shaheen
Professor Ruth Plummer
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study2023
12345678910111213